Organization
Harbin, China
4 abstracts
Abstract
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.Org: Zhengzhou, China, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Luoyang, China, Hunan Provincial Tumor Hospital, Changsha, China,
Abstract
Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.Org: Harbin Medical University Cancer Hospital, Harbin, China,
Abstract
TACE-HAIC combined with donafenib and immunotherapy for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A retrospective analysis.Org: Harbin Medical University Cancer Hospital, Harbin, China,
Abstract
Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.Org: Harbin Medical University Cancer Hospital, Harbin, China,